Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers

Cornea

Volumn 29, Issue 3, 2010, Pages 263-268

  Walters, Thomas ^a   Rinehart, Mike ^b   Krebs, William ^b   Holdbrook, Mark ^b  

^a Keystone Research   (United States)

^b SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bacterial keratitis; Fluoroquinolones; Levofloxacin; Ofloxacin; Pharmacokinetics

Indexed keywords

LEVOFLOXACIN; OFLOXACIN; ROSE BENGAL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENOPIA; BEDTIME DOSAGE; BIOMICROSCOPY; CLINICAL EVALUATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSGEUSIA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INCIDENCE; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORNING DOSAGE; OPHTHALMOSCOPY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT WITHDRAWAL; VISUAL ACUITY; VOLUNTEER;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ACOUSTIC; MIDDLE AGED; OFLOXACIN; OPHTHALMIC SOLUTIONS; OPHTHALMOSCOPY; TEARS; VISUAL ACUITY; YOUNG ADULT;

EID: 77649177221     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181b55fce     Document Type: Article

References (20)

1. Ogawa G, Hyndiuk R. The fluoroquinolones: new antibiotics in ophthalmology. Int Ophthalmol Clin. 1993;33:59-68.
2. Drlica K. Mechanism of fluoroquinolone action. Curr Opin Microbiol. 1999;2:504-508.
3. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis. 2000;31(Suppl 2):S24-S28.
4. Ernst M, Ernst E, Klepser M. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones? Am J Health Syst Pharm. 1997;54: 2569-2584.
5. Martin S, Meyer J, Chuck S, et al. Levofloxacin and sparfloxacin: new quinolone antibiotics. Ann Pharmacother. 1998;32:320-336.
6. Graves A, Henry M, O'Brien T, et al. In vitro susceptibilities of bacterial ocular isolates. Cornea. 2001;20:301-305.
7. NDA 21-199, Microbiology Review. Washington, DC: FDA/Center for Drug Evaluation and Research; 2000.
8. Ross DL, Riley CM. Aqueous solubility of some variously substituted quinolone antimicrobials. Int J Pharm. 1990;63:237-250.
9. Bui DP, Dang SB, Hwang DG Effect of ciprofloxacin concentration on mutational resistance rates in S. aureus. Invest Ophthalmol Vis Sci. 1995; 36 Abstract 4876.
10. Iquix Prescribing Information. Napa, CA: Santen Incorporated; 2007.
11. McDonald MB. Research review and update: IQUIX (levofloxacin 1.5%). Int Ophthalmol Clin. 2006;46:47-60.
12. Abbott RL, Asbell PA, Sahm DF. Ocular TRUST: a new tool for ophthalmology. Ophthalmology Times. 2007;1:1-4.
13. Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol. 2008 Mar 27 [Epub ahead of print].
14. Raizman MB, Rubin JM, Graves AL, et al. Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers. Clin Ther. 2002; 24:1439-1450.
15. AAO (American Academy of Ophthalmology) Preferred Practice Pattern®: Bacterial Keratitis. 2005. Available at: www.aao.org/education/guidelines/ppp/ bacterial-keratitis.cfm. Accessed February 18, 2008.
16. Highlights from an expert roundtable discussion, Hawaiian Eye 2008. Fluoroquinolone pharmacodynamics, penetration, and persistence. Ophthalmol Times. 2008;Suppl:1-9.
17. Clark L, Bezwada P, Hosoi K, et al. Comprehensive evaluation of ocular toxicity of topical levofloxacin in rabbit and primate models. J Toxicol Cutaneous Ocul Toxicol. 2004;23:1-18.
18. Skelnik DL, Clark LA, Bezwada P. In vitro efect of drug concentration and exposure time of levofloxacin, ofloxacin, gatifloxacin, and moxifloxacin on human corneal endothelial cells and keratocytes. Presented at the ARVO Annual Meeting; May 4-9, 2003; Ft. Lauderdale, FL. Poster #4739.
19. Gramates P, McDonald M, Salib G, et al. Safety and efficacy of levofloxacin 1.5% eyedrops in nonhuman primates having penetrating keratoplasty: clinical and laboratory findings. J Cataract Refract Surg. 2005;31:1995-1998.
20. Holland E, McCarthy M, Holland S. The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery. Curr Med Res Opin. 2007;23: 2955-2960.